Skip to content
TrialScanner

NCT07946848

Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.

Phase 2Not yet recruitingIMRXLead

Registry record

Lead sponsor
Immuneering Corporation
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer); Non-Squamous Non Small Cell Lung Cancer; Metastatic Non-Small Lung Cell Cancer; Locally Advanced Non-Small Cell Lung Cancer; Lung Cancer (NSCLC)
Primary completion
May 2029Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT07946848 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT07946848: Phase 2 Study to Evaluate... | TrialScanner